Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice

Atsushi Sadanaga, Hitoshi Nakashima, Kohsuke Masutani, Katsuhisa Miyake, Sakiko Shimizu, Takashi Igawa, Naonobu Sugiyama, Hiroaki Niiro, Hideki Hirakata, Mine Harada

研究成果: ジャーナルへの寄稿記事

48 引用 (Scopus)

抄録

Objective. To examine whether the platelet-derived growth factor (PDGF) receptor antagonist imatinib ameliorates glomerulonephritis in MRL/lpr mice, a condition that is similar to severe lupus nephritis in humans. Methods. Sixteen-week-old MRL/lpr female mice having an advanced stage of glomerulonephritis were divided into 3 groups according to treatment: 1) 50 mg/kg or 2) 10 mg/kg of imatinib (administered orally 4 times a week up to 24 weeks of age) or 3) vehicle solution (untreated group). The histopathologic condition of the kidneys and salivary glands of each mouse as well as the cumulative survival rates, extent of lymphadenopathy and splenomegaly, and serum chemistry and immunologic values were assessed. Results. In mice treated with 50 mg/kg imatinib, neither proliferation of glomerular cells nor crescent formation occurred. A drastic decrease in mesangial matrix was noted. Mice treated with 50 mg/kg imatinib had a prolonged life span compared with mice treated with 10 mg/kg imatinib and untreated mice. Expression of PDGF receptor and transforming growth factor β messenger RNA in the kidneys was significantly reduced in the 50 mg/kg imatinib-treated mice compared with that in the 10 mg/kg imatinib-treated mice (P < 0.05) and the untreated mice (P < 0.01). Intriguingly, lymphadenopathy and salivary gland inflammation were also attenuated in imatinib-treated mice, in a dose-dependent manner. Serum levels of IgG and antidouble-stranded DNA antibodies were also reduced in the imatinib-treated mice. Conclusion. These findings indicate that imatinib has a pleiotropic therapeutic effect, namely, the inhibition of PDGF signaling and immunosuppression, on the glomerulonephritis of MRL/lpr mice, which suggests a potential application of this drug in the treatment of human lupus nephritis.

元の言語英語
ページ(範囲)3987-3996
ページ数10
ジャーナルArthritis and rheumatism
52
発行部数12
DOI
出版物ステータス出版済み - 12 1 2005

Fingerprint

Inbred MRL lpr Mouse
Nephritis
Glomerulonephritis
Platelet-Derived Growth Factor Receptors
Lupus Nephritis
Imatinib Mesylate
Sialadenitis
Kidney
Platelet-Derived Growth Factor
Splenomegaly
Transforming Growth Factors
Therapeutic Uses
Salivary Glands
Serum
Immunosuppression
Immunoglobulin G

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

これを引用

Sadanaga, A., Nakashima, H., Masutani, K., Miyake, K., Shimizu, S., Igawa, T., ... Harada, M. (2005). Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis and rheumatism, 52(12), 3987-3996. https://doi.org/10.1002/art.21424

Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. / Sadanaga, Atsushi; Nakashima, Hitoshi; Masutani, Kohsuke; Miyake, Katsuhisa; Shimizu, Sakiko; Igawa, Takashi; Sugiyama, Naonobu; Niiro, Hiroaki; Hirakata, Hideki; Harada, Mine.

:: Arthritis and rheumatism, 巻 52, 番号 12, 01.12.2005, p. 3987-3996.

研究成果: ジャーナルへの寄稿記事

Sadanaga, A, Nakashima, H, Masutani, K, Miyake, K, Shimizu, S, Igawa, T, Sugiyama, N, Niiro, H, Hirakata, H & Harada, M 2005, 'Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice', Arthritis and rheumatism, 巻. 52, 番号 12, pp. 3987-3996. https://doi.org/10.1002/art.21424
Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T その他. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis and rheumatism. 2005 12 1;52(12):3987-3996. https://doi.org/10.1002/art.21424
Sadanaga, Atsushi ; Nakashima, Hitoshi ; Masutani, Kohsuke ; Miyake, Katsuhisa ; Shimizu, Sakiko ; Igawa, Takashi ; Sugiyama, Naonobu ; Niiro, Hiroaki ; Hirakata, Hideki ; Harada, Mine. / Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. :: Arthritis and rheumatism. 2005 ; 巻 52, 番号 12. pp. 3987-3996.
@article{d8d02111622749c5b90c320cb012e0d1,
title = "Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice",
abstract = "Objective. To examine whether the platelet-derived growth factor (PDGF) receptor antagonist imatinib ameliorates glomerulonephritis in MRL/lpr mice, a condition that is similar to severe lupus nephritis in humans. Methods. Sixteen-week-old MRL/lpr female mice having an advanced stage of glomerulonephritis were divided into 3 groups according to treatment: 1) 50 mg/kg or 2) 10 mg/kg of imatinib (administered orally 4 times a week up to 24 weeks of age) or 3) vehicle solution (untreated group). The histopathologic condition of the kidneys and salivary glands of each mouse as well as the cumulative survival rates, extent of lymphadenopathy and splenomegaly, and serum chemistry and immunologic values were assessed. Results. In mice treated with 50 mg/kg imatinib, neither proliferation of glomerular cells nor crescent formation occurred. A drastic decrease in mesangial matrix was noted. Mice treated with 50 mg/kg imatinib had a prolonged life span compared with mice treated with 10 mg/kg imatinib and untreated mice. Expression of PDGF receptor and transforming growth factor β messenger RNA in the kidneys was significantly reduced in the 50 mg/kg imatinib-treated mice compared with that in the 10 mg/kg imatinib-treated mice (P < 0.05) and the untreated mice (P < 0.01). Intriguingly, lymphadenopathy and salivary gland inflammation were also attenuated in imatinib-treated mice, in a dose-dependent manner. Serum levels of IgG and antidouble-stranded DNA antibodies were also reduced in the imatinib-treated mice. Conclusion. These findings indicate that imatinib has a pleiotropic therapeutic effect, namely, the inhibition of PDGF signaling and immunosuppression, on the glomerulonephritis of MRL/lpr mice, which suggests a potential application of this drug in the treatment of human lupus nephritis.",
author = "Atsushi Sadanaga and Hitoshi Nakashima and Kohsuke Masutani and Katsuhisa Miyake and Sakiko Shimizu and Takashi Igawa and Naonobu Sugiyama and Hiroaki Niiro and Hideki Hirakata and Mine Harada",
year = "2005",
month = "12",
day = "1",
doi = "10.1002/art.21424",
language = "English",
volume = "52",
pages = "3987--3996",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice

AU - Sadanaga, Atsushi

AU - Nakashima, Hitoshi

AU - Masutani, Kohsuke

AU - Miyake, Katsuhisa

AU - Shimizu, Sakiko

AU - Igawa, Takashi

AU - Sugiyama, Naonobu

AU - Niiro, Hiroaki

AU - Hirakata, Hideki

AU - Harada, Mine

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Objective. To examine whether the platelet-derived growth factor (PDGF) receptor antagonist imatinib ameliorates glomerulonephritis in MRL/lpr mice, a condition that is similar to severe lupus nephritis in humans. Methods. Sixteen-week-old MRL/lpr female mice having an advanced stage of glomerulonephritis were divided into 3 groups according to treatment: 1) 50 mg/kg or 2) 10 mg/kg of imatinib (administered orally 4 times a week up to 24 weeks of age) or 3) vehicle solution (untreated group). The histopathologic condition of the kidneys and salivary glands of each mouse as well as the cumulative survival rates, extent of lymphadenopathy and splenomegaly, and serum chemistry and immunologic values were assessed. Results. In mice treated with 50 mg/kg imatinib, neither proliferation of glomerular cells nor crescent formation occurred. A drastic decrease in mesangial matrix was noted. Mice treated with 50 mg/kg imatinib had a prolonged life span compared with mice treated with 10 mg/kg imatinib and untreated mice. Expression of PDGF receptor and transforming growth factor β messenger RNA in the kidneys was significantly reduced in the 50 mg/kg imatinib-treated mice compared with that in the 10 mg/kg imatinib-treated mice (P < 0.05) and the untreated mice (P < 0.01). Intriguingly, lymphadenopathy and salivary gland inflammation were also attenuated in imatinib-treated mice, in a dose-dependent manner. Serum levels of IgG and antidouble-stranded DNA antibodies were also reduced in the imatinib-treated mice. Conclusion. These findings indicate that imatinib has a pleiotropic therapeutic effect, namely, the inhibition of PDGF signaling and immunosuppression, on the glomerulonephritis of MRL/lpr mice, which suggests a potential application of this drug in the treatment of human lupus nephritis.

AB - Objective. To examine whether the platelet-derived growth factor (PDGF) receptor antagonist imatinib ameliorates glomerulonephritis in MRL/lpr mice, a condition that is similar to severe lupus nephritis in humans. Methods. Sixteen-week-old MRL/lpr female mice having an advanced stage of glomerulonephritis were divided into 3 groups according to treatment: 1) 50 mg/kg or 2) 10 mg/kg of imatinib (administered orally 4 times a week up to 24 weeks of age) or 3) vehicle solution (untreated group). The histopathologic condition of the kidneys and salivary glands of each mouse as well as the cumulative survival rates, extent of lymphadenopathy and splenomegaly, and serum chemistry and immunologic values were assessed. Results. In mice treated with 50 mg/kg imatinib, neither proliferation of glomerular cells nor crescent formation occurred. A drastic decrease in mesangial matrix was noted. Mice treated with 50 mg/kg imatinib had a prolonged life span compared with mice treated with 10 mg/kg imatinib and untreated mice. Expression of PDGF receptor and transforming growth factor β messenger RNA in the kidneys was significantly reduced in the 50 mg/kg imatinib-treated mice compared with that in the 10 mg/kg imatinib-treated mice (P < 0.05) and the untreated mice (P < 0.01). Intriguingly, lymphadenopathy and salivary gland inflammation were also attenuated in imatinib-treated mice, in a dose-dependent manner. Serum levels of IgG and antidouble-stranded DNA antibodies were also reduced in the imatinib-treated mice. Conclusion. These findings indicate that imatinib has a pleiotropic therapeutic effect, namely, the inhibition of PDGF signaling and immunosuppression, on the glomerulonephritis of MRL/lpr mice, which suggests a potential application of this drug in the treatment of human lupus nephritis.

UR - http://www.scopus.com/inward/record.url?scp=29144476588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144476588&partnerID=8YFLogxK

U2 - 10.1002/art.21424

DO - 10.1002/art.21424

M3 - Article

C2 - 16320345

AN - SCOPUS:29144476588

VL - 52

SP - 3987

EP - 3996

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -